Clinical Trial Update: Safety of Astepro 0.15% Nasal Spray and Astepro 0.1% Nasal Spray in Children Ages >6 Months to <6 Years With AR [Phase 4]

View source ↗

Summary

Phase 4 safety evaluation of Astepro nasal sprays (0.15% and 0.1%) in children aged >6 months to <6 years with allergic rhinitis; results were posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Rhinitis

Drugs mentioned

• Astepro 0.1% Nasal Spray (azelastine)
• Astepro 0.15% Nasal Spray (azelastine)

Snippet

Sponsor: Meda Pharmaceuticals | Conditions: Allergic Rhinitis | Phase 4 | Status: COMPLETED | Results posted: 2015-06-29